Viewing Study NCT07474558


Ignite Creation Date: 2026-03-26 @ 3:18 PM
Ignite Modification Date: 2026-03-31 @ 2:25 AM
Study NCT ID: NCT07474558
Status: NOT_YET_RECRUITING
Last Update Posted: 2026-03-16
First Post: 2026-02-25
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates
Sponsor: Jules Bordet Institute
Organization:

Study Overview

Official Title: SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates
Status: NOT_YET_RECRUITING
Status Verified Date: 2026-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: SCARLET-ICE
Brief Summary: The goal of this interventional study is to determine if scalp cooling (by the Paxman Scalp Cooling System) reduces the extent and severity of alopecia in participants with advanced solid tumours receiving ADC.

The main question it aims to evaluate the efficacy of scalp cooling in reducing chemotherapy-induced alopecia in participants with advanced/metastatic solid tumours receiving antibody-drug conjugates (trastuzumab-deruxtecan, sacituzumab-govitecan, or datopotamab-deruxtecan), as assessed by blinded central dermatological review.

Researchers will compare the experimental arm (ADC treatment + scalp cooling) with the control arm (ADC only). Scalp cooling will be done each day of ADC treatment : before, during and post-infusions of their ADC treatment.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: